Start with acne, then reuse UniProt P22894 as the stable protein anchor across project notes and exports.
CHEMBL4588 Target Snapshot
Neutrophil collagenase · SINGLE PROTEIN · Homo sapiens
Research home keeps recent targets
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Switch target
Move to another high-traffic target or paste a specific ChEMBL target ID.
Frame the target before identity details
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Neutrophil collagenase shows approved-linked disease relevance led by acne. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P22894. Start with acne, then reuse UniProt P22894 as the stable protein anchor across project notes and exports.
Neutrophil collagenase shows approved-linked disease relevance led by acne. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with acne because it currently carries approved-linked support. Linked drugs include DOXYCYCLINE, DOXYCYCLINE HYCLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyNeutrophil collagenase
Review this target as Neutrophil collagenase, mapped to UniProt P22894. Sequence length is 467 aa.
Protein source · UniProt accession via ChEMBL component mappingCross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Neutrophil collagenase as ChEMBL target CHEMBL4588, mapped to UniProt P22894. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Start with the right source
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Neutrophil collagenase is the right protein anchor across sources, using UniProt P22894 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why acne is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardBasic Information
Verify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Neutrophil collagenase |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P22894 |
Next Actions
UniProt Target Context
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Neutrophil collagenase |
| UniProt Accession | P22894 |
| Component Type | Protein |
| Sequence Length | 467 aa |
Neutrophil collagenase
How to read this target
Review this target as Neutrophil collagenase, mapped to UniProt P22894. Sequence length is 467 aa.
Disease Relevance & Evidence Level
Open Targets-ready disease context using the current target-indication evidence contract.
Neutrophil collagenase shows approved-linked disease relevance led by acne. 5 more disease programs remain visible in the same review block.
How to read disease relevance
Start review with acne because it currently carries approved-linked support. Linked drugs include DOXYCYCLINE, DOXYCYCLINE HYCLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Clinical Phase Distribution
Activity Type Distribution
Top Inhibitors (by pChEMBL)
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL2064547 | 10.7 | IC50 | 0.02 | Preclinical |
| CHEMBL2064548 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL2064549 | 10.4 | IC50 | 0.04 | Preclinical |
| CHEMBL11306 | 10.34 | IC50 | 0.046 | Preclinical |
| CHEMBL2425938 | 10.3 | IC50 | 0.05 | Preclinical |
| CHEMBL440498 | 10.01 | IC50 | 0.097 | Clinical |
| CHEMBL306524 | 10.0 | Ki | 0.1 | Preclinical |
| CHEMBL293503 | 10.0 | Ki | 0.1 | Preclinical |
| CHEMBL2064542 | 9.96 | IC50 | 0.11 | Preclinical |
| CHEMBL70417 | 9.96 | Ki | 0.11 | Preclinical |
pChEMBL Value Distribution
Assay Landscape
Binding — 220 assays, 1,317 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 200 | 1,194 | 7.1 |
| assay format | 11 | 30 | 5.5 |
| cell-based format | 9 | 93 | 5.3 |
ADME — 9 assays, 27 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 7 | 22 | 6.8 |
| assay format | 2 | 5 | 7.1 |
Unassigned — 1 assays, 0 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 0 | — |